Are you under pressure to identify new antibody therapeutic targets?
In our 2012 European Antibody Congress Survey we asked the industry for their top tip in identifying these new targets.
We received a multitude of responses but the most frequent answer was associated with understanding disease biology.
Having validation of the biology and an in-depth knowledge into its mechanism of action, alongside the willingness, (financial) backing and patience to take the risk, were all seen as key requirements when undertaking this task.
Would you agree?
Do you want to find out what else our survey showed?